Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June’s Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life.
Cutera’s acne survey data sheds light on the emotional and physical aspects of acne in day-to-day life including the effect on memory-making moments, and the importance of new approaches in treating acne.
The survey data highlights the following key insights:
- 90% of acne sufferers surveyed experience daily insecurities related to their acne.
- 43% of acne sufferers surveyed worry they will never have clear skin.
- 6 in 10 say the struggles in treating acne can be worse than the acne itself.
- Half of those who have heard of AviClear are interested in trying it.
The survey data also revealed that 81% of acne sufferers surveyed wish they knew more about in-office treatments, with lasers being the #1 acne treatment that sufferers are considering1. This data validates the market demand that Cutera proactively identified, ultimately leading to the development of AviClear, a solution that effectively addresses the significant gap in acne treatment options.
“At Cutera, we believe in transforming lives through the advancement of our technologies,” said Taylor Harris, CEO of Cutera. “We understand the significant toll that acne has on individuals, and we are dedicated to introducing treatments like AviClear that help people overcome insecurities and embrace life with confidence. We continue to invest in research and innovation, driven by our passion to make a meaningful impact on the lives of those we serve.”
